Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its pioneering efforts to develop ...

Smith & Nephew (NYSE:SNN) quickly edged higher by ~1% after a report that it's considering a break-up amid activist pressure.

Smith & Nephew Plc的财务健康状况根据公司超100多个因子相比发达市场中医疗保健行业内其他公司的排名确定。

Berenberg raised the firm’s price target on Smith & Nephew to 1,100 GBp from 1,050 GBp and keeps a Hold rating on the shares.Discover the ...

Smith+Nephew submitted its TESSA System for FDA 510 (k) clearance, according to a March 4 news release. TESSA, which stands for Tracking Enabled Spatial Surgery Assistant, is pending FDA clearance for ...

2024年全年，Smith+Nephew实现收入58.10亿美元，较2023年的55.49亿美元有所增长，基础收入增长5.3%。报告显示增长4.7%，其中包含-60个基点的汇率不利影响。根据 InvestingPro ...

The medical-technology company was boosted by its sports medicine segment and an improved trading margin.

Smith+Nephew announced today that it aims to develop technology in a new field of arthroscopic surgical innovation.

Despite ongoing pressures in China, revenue and trading profit at the FTSE 100 firm rose 5.3% and 8.2% respectively in 2024.

Smith & Nephew Plc Chief Executive Officer Deepak Nath said a transformation plan unveiled two years ago will clearly start ...

The Smith & Nephew share price jumped today after the company announced a strong performance last year. Is this writer ready ...

Smith+Nephew reported higher revenue growth for 2024, as the company’s 12-Point Plan delivered growth and lower costs.